Jagsonpal Pharmaceuticals will hold its 47th Annual General Meeting on September 18, 2026, to approve a 200% dividend payout for FY26. The pharmaceutical firm reported a 19% year-on-year rise in operating profit after tax to ₹446 crore, driven by disciplined cost management and portfolio optimization.

The Board has recommended a dividend of ₹4 per equity share, comprising a ₹2.50 final dividend and a ₹1.50 special dividend. This follows a successful ₹40 crore share buyback executed in May 2026 at a premium of approximately 40% over the market price.

Financial Performance

Revenue from operations grew by 6.9% to ₹2,872 crore in FY26, up from ₹2,687 crore in the previous fiscal year. Operating EBITDA stood at ₹609 crore with a margin of 21.2%, reflecting a slight moderation from the 21.5% recorded in FY25 despite higher revenues.

Profit before tax increased to ₹596 crore from ₹502 crore in FY25. However, reported profit after tax was ₹431 crore, lower than the ₹554 crore in FY25, primarily due to exceptional items including an impact of newly notified labour codes amounting to ₹21 crore.

Strategic Developments

Jagsonpal acquired an 85% equity stake in Aequitas Healthcare Private Limited in July 2026 for ₹20.8 crore, marking its entry into the hospital segment. Aequitas generated revenues of ₹53 crore in FY26 and brings established relationships with leading hospital chains.

The company also highlighted strong brand performance, with its top 10 brands contributing 58% of total revenue. Indocap emerged as the first brand to cross ₹50 crore in sales, reinforcing leadership in pain management therapies.

What the Numbers Show

The divergence between operating profit growth (19%) and revenue growth (7%) indicates significant operating leverage. Additionally, free cash flow conversion remained robust at nearly 100% of EBITDA, enabling substantial shareholder returns through dividends and buybacks while maintaining a net cash position of ₹1,907 crore.

Jagsonpal Pharmaceuticals has filed its Business Responsibility and Sustainability Report (BRSR) for the financial year ending March 31, 2026. The report details the company’s adherence to the National Guidelines on Responsible Business Conduct (NGRBC) across nine principles.

The disclosure covers governance structures, environmental impact, and social responsibility initiatives. Jagsonpal operates primarily in the marketing and distribution of pharmaceutical formulations, contributing 99.42% to its total turnover. The company reported a turnover of ₹2,872.25 million and a net worth of ₹2,942.09 million for the period.

Employee Welfare and Safety

The company employed 1,305 individuals as of March 31, 2026, comprising 1,297 permanent employees and 8 non-permanent staff. Women constitute 2% of the total workforce. The report notes that 100% of permanent male employees and 100% of female employees received health and life insurance coverage.

Safety incidents remain a focus area. The company recorded 16 road accidents involving employees in FY26, down from 25 in the previous year. Tragically, there was 1 fatality reported in FY26, consistent with the prior year’s figure. The company provided monetary support for hospitalization and post-discharge care through group insurance policies.

Environmental Impact and Waste Management

As a marketing and distribution entity without manufacturing facilities, Jagsonpal’s direct environmental footprint is limited to office operations and waste disposal. Total electricity consumption at the corporate office and warehouse stood at 1,07,869.3 kWh.

Waste management primarily involves the disposal of expired and damaged pharmaceutical goods. The company disposed of 39,122 kg of such waste via incineration in FY26, a decrease from 43,070 kg in FY25. All waste was handled by government-approved vendors to prevent re-entry into the market.

Governance and Stakeholder Engagement

The Board of Directors includes 33% women representation. No fines or penalties were paid to regulatory agencies during the year. The company resolved all 5 shareholder complaints and 7 customer complaints received in FY26, leaving zero pending cases.

What the Numbers Show

The reduction in waste disposal volume from 43,070 kg to 39,122 kg suggests improved inventory management or reduced product damage rates, aligning with operational efficiency goals despite the absence of manufacturing overheads.